About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback